Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF

Summary

APERITIF is a prospective randomized open-label, blinded end-point (PROBE) trial, nested in the ongoing the "FRENCHIE" registry, a French multicenter prospective observational study granted by "ANR-RHU Grand Emprunt", in which all consecutive patients admitted within 48 hours after symptom onset in a cardiac Intensive Care Unit (ICU) for an acute myocardial infarction (AMI) are included (NCT04050956). Among them, eligible Patients for "APERITIF" will be randomized into two groups: Dual Anti-Platelet Therapy (DAPT) alone or DAPT plus rivaroxaban 2.5mg twice daily for 4 weeks, prescribed as soon as possible after admission and completion of the initial percutaneous coronary intervention/angiography procedure.

Timeline

Start

2021-10-10

Primary completion

2023-03-10

Completion

2024-02-09

Publications

• Puymirat E, Soulat G, Lattuca B, Bouleti C, Delarche N, Roubille F, Cottin Y, Bression D, Combaret N, Gerbaud E, Lhermusier T, Biere L, Dubreuil O, Mousseaux E, Steg PG, Cayla G, Lemesle G, Silvain J, Dillinger JG, Georges JL, Ducrocq G, Genet T, Morelle JF, Montalescot G, Berard L, Rousseau A, Soen M, Simon T, Danchin N; APERITIF study investigators. Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial. JAMA Cardiol. 2026 Apr 1;11(4):323-331. doi: 10.1001/jamacardio.2026.0026.
• Puymirat E, Soulat G, Fayol A, Mousseaux E, Montalescot G, Cayla G, Steg PG, Berard L, Rousseau A, Drouet E, Simon T, Danchin N; APERITIF study investigators. Rationale and design of the direct oral anticoagulants for prevention of left ventricular thrombus after anterior acute myocardial infarction (APERITIF) trial. Am Heart J. 2023 Dec;266:98-105. doi: 10.1016/j.ahj.2023.09.005. Epub 2023 Sep 14.

Drugs

Indications